Skip to main content
Erschienen in:

23.06.2023 | Herzinsuffizienz | Fortbildung

SGLT-2-Inhibitoren, GLP-1-Rezeptoragonisten, Mineralokortikoidrezeptorantagonisten

Die neuen Wunderdrogen - eine Einordnung aus kardiologischer Sicht

verfasst von: Prof. Dr. Dr. Stefan H. Schirmer

Erschienen in: Info Diabetologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Auszug

GLP-1-Rezeptoragonisten und SGLT-2-Inhibitoren haben es aus kardiologischer Sicht nicht nur ermöglicht, dass mit der Therapie des Diabetes mellitus auch relevante kardiovaskuläre Endpunkte adressiert werden. Sie haben sich in der Kardiologie auch als Substanzen etabliert, die unabhängig vom Vorliegen eines Diabetes mellitus eingesetzt werden können. Heute sind SGLT-2-Inhibitoren aus der Therapie der Herz- und Niereninsuffizienz nicht mehr wegzudenken.
Literatur
1.
Zurück zum Zitat Parker FR. Department of Health and Human Services, US Food and Drug Administration: Authority and Responsibility. FDA Administrative Enforcement Manual: CRC Press; 2005. p. 21-60 Parker FR. Department of Health and Human Services, US Food and Drug Administration: Authority and Responsibility. FDA Administrative Enforcement Manual: CRC Press; 2005. p. 21-60
2.
Zurück zum Zitat Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28 Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28
3.
Zurück zum Zitat Wiviott SD et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57 Wiviott SD et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57
4.
Zurück zum Zitat Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22 Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22
5.
Zurück zum Zitat Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30 Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30
6.
Zurück zum Zitat Cosentino F et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323 Cosentino F et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323
7.
Zurück zum Zitat Marx N. Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. Eur Heart J. 2020;41[35):3359-62 Marx N. Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. Eur Heart J. 2020;41[35):3359-62
9.
Zurück zum Zitat Davies MJ et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86 Davies MJ et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86
10.
Zurück zum Zitat Nathan DM et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022;387(12):1075-88 Nathan DM et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022;387(12):1075-88
11.
Zurück zum Zitat Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-50 Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-50
12.
Zurück zum Zitat Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. Reply. N Engl J Med. 2023;388(12):1146 Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. Reply. N Engl J Med. 2023;388(12):1146
13.
Zurück zum Zitat Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-15 Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-15
14.
Zurück zum Zitat Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-45 Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-45
15.
Zurück zum Zitat Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-16 Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-16
16.
Zurück zum Zitat Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-81 Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-81
17.
Zurück zum Zitat Savarese G et al. Cardiovascular effects of non-insulin Glukose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res. 2022;118(10):2231-52 Savarese G et al. Cardiovascular effects of non-insulin Glukose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res. 2022;118(10):2231-52
18.
Zurück zum Zitat van Veldhuisen SL et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955-69 van Veldhuisen SL et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955-69
19.
Zurück zum Zitat Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-9 Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-9
20.
Zurück zum Zitat McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008 McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008
21.
Zurück zum Zitat Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24 Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24
22.
Zurück zum Zitat Zannad F et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-29 Zannad F et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-29
23.
Zurück zum Zitat Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glukose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422-34 Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glukose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422-34
24.
Zurück zum Zitat McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726 McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726
25.
Zurück zum Zitat Owan TE et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9 Owan TE et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9
26.
Zurück zum Zitat Vaduganathan M et al. Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation. 2022;145(23):1741-3 Vaduganathan M et al. Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation. 2022;145(23):1741-3
27.
Zurück zum Zitat Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-61 Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-61
28.
Zurück zum Zitat Solomon SD et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217-25 Solomon SD et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217-25
29.
Zurück zum Zitat Vaduganathan M et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022;400(10354):757-67 Vaduganathan M et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022;400(10354):757-67
30.
Zurück zum Zitat Braunwald E. SGLT2 inhibitors: the statins of the 21st century. Eur Heart J. 2022;43(11):1029-30 Braunwald E. SGLT2 inhibitors: the statins of the 21st century. Eur Heart J. 2022;43(11):1029-30
31.
Zurück zum Zitat Heidenreich PA et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e94 Heidenreich PA et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e94
32.
Zurück zum Zitat Voors AA et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568-74 Voors AA et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568-74
33.
Zurück zum Zitat von Lewinski D et al. Empagliflozin in acute myocardial infarction: the EMMY trial European Heart Journal. 2022;43(41):4421-32 von Lewinski D et al. Empagliflozin in acute myocardial infarction: the EMMY trial European Heart Journal. 2022;43(41):4421-32
34.
Zurück zum Zitat Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46 Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46
35.
Zurück zum Zitat Group* TE-KC. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022;388:117-27 Group* TE-KC. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022;388:117-27
36.
Zurück zum Zitat Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179(13):3220-34 Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179(13):3220-34
37.
Zurück zum Zitat Bakris GL et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29 Bakris GL et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29
38.
Zurück zum Zitat Pitt B et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-63 Pitt B et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-63
39.
Zurück zum Zitat Agarwal R et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84 Agarwal R et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84
Metadaten
Titel
SGLT-2-Inhibitoren, GLP-1-Rezeptoragonisten, Mineralokortikoidrezeptorantagonisten
Die neuen Wunderdrogen - eine Einordnung aus kardiologischer Sicht
verfasst von
Prof. Dr. Dr. Stefan H. Schirmer
Publikationsdatum
23.06.2023
Verlag
Springer Medizin
Erschienen in
Info Diabetologie / Ausgabe 3/2023
Print ISSN: 1865-5459
Elektronische ISSN: 2196-6362
DOI
https://doi.org/10.1007/s15034-023-4512-7

Weitere Artikel der Ausgabe 3/2023

Info Diabetologie 3/2023 Zur Ausgabe

Passend zum Thema

ANZEIGE

SGLT-2-Inhibitoren für alle Patient:innen mit chronischer Herzinsuffizienz empfohlen

Das ESC-Leitlinien-Update 2023 bedeutet einen Paradigmenwechsel in der Behandlung der Herzinsuffizienz (HF), denn nun werden SGLT-2i sowohl für HFrEF, als auch für HFmrEF und HFpEF empfohlen. Somit können jetzt alle Patient:innen mit HF von SGLT-2i als zentralem Bestandteil der Therapie profitieren.

ANZEIGE

Dapagliflozin als neue Therapieoption zur Behandlung einer Herzinsuffizienz unabhängig von der Ejektionsfraktion

Dapagliflozin ist nun zur Behandlung aller Patient:innen mit chronischer symptomatischer Herzinsuffizienz zugelassen und bietet somit auch neue Hoffnung für die Therapie von jenen mit HFpEF. In der DELIVER-Studie zeigte der SGLT-2-Inhibitor eine signifikante Reduktion von Herzinsuffizienz-Hospitalisierungen und CV-Todesfällen.

ANZEIGE

ACS-Erstlinientherapie: Konsensbeschluss rät zur DAPT mit Ticagrelor

Ein Konsortium führender Fachgesellschaften erarbeitete jüngst auf Basis umfangreicher Metaanalysen einen Konsens für die Therapie koronarer Herzkrankheiten. Was dabei auffiel: Die duale Plättchenhemmung (DAPT) mit Ticagrelor ist die bevorzugte Therapieoption für das akute Koronarsyndrom (ACS).